Pharmacogenomics of cytochrome p450 of nimodipine metabolism after aneurysmal subarachnoid hemorrhage

Sarah H. Peacock, Courtney James, Marion T. Turnbull, Jennifer B. Cowart, Joel M. Reid, W. David Freeman

Research output: Contribution to journalArticle

Abstract

INTRODUCTION Aneurysmal subarachnoid hemorrhage (aSAH) is a type of stroke that is life threatening with high rates of mortality, and many survivors are left with permanent neurologic deficits. Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia. It is the only evidence-based medication that has been shown to have improved outcomes for delayed cerebral ischemia; therefore, it is important for neuroscience nurses to be knowledgeable of the pharmacology and pharmacogenomics properties of this medication, including cytochrome P450 (CYP450) enzymes. METHODS AND RESULTS This article reviews the CYP450 enzyme system including a review of the pharmacotherapy and pharmacogenomics of nimodipine for patients with aSAH illustrated with case study of a patient with abnormal drug metabolism. CONCLUSION CYP450 enzymes can be inhibited or induced by multiple medications resulting in clinically significant differences in drug metabolism. Food and Drug Administration-approved medication nimodipine is the only medication shown to improve outcomes in patients with aSAH. Hence, it is important to have awareness of potential drug-to-drug interactions and pharmacogenomics of nimodipine when caring for critically ill patients with aSAH.

Original languageEnglish (US)
Pages (from-to)238-242
Number of pages5
JournalJournal of Neuroscience Nursing
Volume51
Issue number5
DOIs
StatePublished - Oct 1 2019

Fingerprint

Nimodipine
Pharmacogenetics
Subarachnoid Hemorrhage
Cytochrome P-450 Enzyme System
Brain Ischemia
Pharmaceutical Preparations
United States Food and Drug Administration
Neurosciences
Neurologic Manifestations
Drug Interactions
Critical Illness
Survivors
Stroke
Nurses
Pharmacology
Drug Therapy
Mortality

Keywords

  • CYP450
  • delayed cerebral ischemia
  • nimodipine
  • pharmacogenomics
  • pharmacotherapy
  • precision medicine
  • subarachnoid hemorrhage

ASJC Scopus subject areas

  • Surgery
  • Endocrine and Autonomic Systems
  • Clinical Neurology
  • Medical–Surgical

Cite this

Pharmacogenomics of cytochrome p450 of nimodipine metabolism after aneurysmal subarachnoid hemorrhage. / Peacock, Sarah H.; James, Courtney; Turnbull, Marion T.; Cowart, Jennifer B.; Reid, Joel M.; Freeman, W. David.

In: Journal of Neuroscience Nursing, Vol. 51, No. 5, 01.10.2019, p. 238-242.

Research output: Contribution to journalArticle

Peacock, Sarah H. ; James, Courtney ; Turnbull, Marion T. ; Cowart, Jennifer B. ; Reid, Joel M. ; Freeman, W. David. / Pharmacogenomics of cytochrome p450 of nimodipine metabolism after aneurysmal subarachnoid hemorrhage. In: Journal of Neuroscience Nursing. 2019 ; Vol. 51, No. 5. pp. 238-242.
@article{488c7a583b5f4ef2b0582e3b7ccce4bc,
title = "Pharmacogenomics of cytochrome p450 of nimodipine metabolism after aneurysmal subarachnoid hemorrhage",
abstract = "INTRODUCTION Aneurysmal subarachnoid hemorrhage (aSAH) is a type of stroke that is life threatening with high rates of mortality, and many survivors are left with permanent neurologic deficits. Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia. It is the only evidence-based medication that has been shown to have improved outcomes for delayed cerebral ischemia; therefore, it is important for neuroscience nurses to be knowledgeable of the pharmacology and pharmacogenomics properties of this medication, including cytochrome P450 (CYP450) enzymes. METHODS AND RESULTS This article reviews the CYP450 enzyme system including a review of the pharmacotherapy and pharmacogenomics of nimodipine for patients with aSAH illustrated with case study of a patient with abnormal drug metabolism. CONCLUSION CYP450 enzymes can be inhibited or induced by multiple medications resulting in clinically significant differences in drug metabolism. Food and Drug Administration-approved medication nimodipine is the only medication shown to improve outcomes in patients with aSAH. Hence, it is important to have awareness of potential drug-to-drug interactions and pharmacogenomics of nimodipine when caring for critically ill patients with aSAH.",
keywords = "CYP450, delayed cerebral ischemia, nimodipine, pharmacogenomics, pharmacotherapy, precision medicine, subarachnoid hemorrhage",
author = "Peacock, {Sarah H.} and Courtney James and Turnbull, {Marion T.} and Cowart, {Jennifer B.} and Reid, {Joel M.} and Freeman, {W. David}",
year = "2019",
month = "10",
day = "1",
doi = "10.1097/JNN.0000000000000464",
language = "English (US)",
volume = "51",
pages = "238--242",
journal = "Journal of Neuroscience Nursing",
issn = "0888-0395",
publisher = "American Association of Neuroscience Nurses",
number = "5",

}

TY - JOUR

T1 - Pharmacogenomics of cytochrome p450 of nimodipine metabolism after aneurysmal subarachnoid hemorrhage

AU - Peacock, Sarah H.

AU - James, Courtney

AU - Turnbull, Marion T.

AU - Cowart, Jennifer B.

AU - Reid, Joel M.

AU - Freeman, W. David

PY - 2019/10/1

Y1 - 2019/10/1

N2 - INTRODUCTION Aneurysmal subarachnoid hemorrhage (aSAH) is a type of stroke that is life threatening with high rates of mortality, and many survivors are left with permanent neurologic deficits. Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia. It is the only evidence-based medication that has been shown to have improved outcomes for delayed cerebral ischemia; therefore, it is important for neuroscience nurses to be knowledgeable of the pharmacology and pharmacogenomics properties of this medication, including cytochrome P450 (CYP450) enzymes. METHODS AND RESULTS This article reviews the CYP450 enzyme system including a review of the pharmacotherapy and pharmacogenomics of nimodipine for patients with aSAH illustrated with case study of a patient with abnormal drug metabolism. CONCLUSION CYP450 enzymes can be inhibited or induced by multiple medications resulting in clinically significant differences in drug metabolism. Food and Drug Administration-approved medication nimodipine is the only medication shown to improve outcomes in patients with aSAH. Hence, it is important to have awareness of potential drug-to-drug interactions and pharmacogenomics of nimodipine when caring for critically ill patients with aSAH.

AB - INTRODUCTION Aneurysmal subarachnoid hemorrhage (aSAH) is a type of stroke that is life threatening with high rates of mortality, and many survivors are left with permanent neurologic deficits. Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia. It is the only evidence-based medication that has been shown to have improved outcomes for delayed cerebral ischemia; therefore, it is important for neuroscience nurses to be knowledgeable of the pharmacology and pharmacogenomics properties of this medication, including cytochrome P450 (CYP450) enzymes. METHODS AND RESULTS This article reviews the CYP450 enzyme system including a review of the pharmacotherapy and pharmacogenomics of nimodipine for patients with aSAH illustrated with case study of a patient with abnormal drug metabolism. CONCLUSION CYP450 enzymes can be inhibited or induced by multiple medications resulting in clinically significant differences in drug metabolism. Food and Drug Administration-approved medication nimodipine is the only medication shown to improve outcomes in patients with aSAH. Hence, it is important to have awareness of potential drug-to-drug interactions and pharmacogenomics of nimodipine when caring for critically ill patients with aSAH.

KW - CYP450

KW - delayed cerebral ischemia

KW - nimodipine

KW - pharmacogenomics

KW - pharmacotherapy

KW - precision medicine

KW - subarachnoid hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85071830152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071830152&partnerID=8YFLogxK

U2 - 10.1097/JNN.0000000000000464

DO - 10.1097/JNN.0000000000000464

M3 - Article

C2 - 31469704

AN - SCOPUS:85071830152

VL - 51

SP - 238

EP - 242

JO - Journal of Neuroscience Nursing

JF - Journal of Neuroscience Nursing

SN - 0888-0395

IS - 5

ER -